First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner
Open Access
- 1 April 2022
- journal article
- editorial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (10) , 3593-3595
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 StandardJournal of Nuclear Medicine, 2021
- Long axial field of view PET scanners: a road map to implementation and new possibilitiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*Journal of Nuclear Medicine, 2019
- Feasibility of PET/CT system performance harmonisation for quantitative multicentre 89Zr studiesEJNMMI Physics, 2018
- 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work upEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010